<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04317430</url>
  </required_header>
  <id_info>
    <org_study_id>NIC2020</org_study_id>
    <nct_id>NCT04317430</nct_id>
  </id_info>
  <brief_title>Niclosamide Role in Diabetic Nephropathy</brief_title>
  <official_title>Possible Role of Niclosamide in Patients With Diabetic Kidney Disease: Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is randomized, controlled, parallel, prospective clinical study will be conducted
      on 60 patients diagnosed with type 2 diabetes mellitus at least five years ago. Patients will
      be recruited from Tanta University Hospital, Tanta, Egypt.

      Accepted patients will be randomized into 2 groups as the following:

      Control group: 30 patients will receive maximum tolerated dose of ACEI plus placebo pills for
      six months Treatment group: 30 patients will receive maximum tolerated dose of ACEI plus
      niclosamide tablets 1 gram once daily for six months The primary end point will be the change
      in Urinary albumin to creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR)
      after six months of treatment
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in urinary albumin creatinine ratio (UACR)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Estimated glomerular filtration rate (eGFR)</measure>
    <time_frame>After 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of Urinary matrix metalloproteinase-7 (MMP-7) level</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Urinary podocalyxin level</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change of Urinary 8-hydroxy-2' -deoxyguanosine (8-OHdG) level</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Diabetic Nephropathies</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Niclosamide tablets 1 gram once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Lactose tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Niclosamide</intervention_name>
    <description>Niclosamide tablets 1 gram once daily</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>lactose tablets</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with Type 2 diabetes mellitus at least 5 years ago

          -  Stage 2 and 3 diabetic nephropathy (persistent micro- or macroalbuminuria with urinary
             albumin creatinine ratio (UACR) &gt;30mg/g) despite treatment with maximum tolerated dose
             of ACE inhibitors for at least 8 weeks prior to the screening

          -  Hemoglobin A1c &gt; 6.5 % with regular use of insulin and/or oral glucose lowering agents

        Exclusion Criteria:

          -  Type 1 diabetes mellitus

          -  Severe renal impairment (eGFR&lt; 30 mL/min/1.73 m2 at screening)

          -  Pregnant or lactating women

          -  Chronic heart failure

          -  Inflammatory or autoimmune disease

          -  History of kidney disease other than diabetic nephropathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Basma M El-fatatry</last_name>
    <phone>201094114899</phone>
    <email>basma.mahrous.clinical@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Faculty of Pharmacy, Tanta University</name>
      <address>
        <city>Tanta</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 18, 2020</study_first_submitted>
  <study_first_submitted_qc>March 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2020</study_first_posted>
  <last_update_submitted>March 19, 2020</last_update_submitted>
  <last_update_submitted_qc>March 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Basma Mahrous El-Fatatry</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>Diabetes - Niclosamide - Diabetic kidney disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niclosamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

